


## Supplementary Figure 1




### Supplementary Figure 1.

(A) Immunoprecipitations of RyR2 and caveolin-3 (Cav-3) followed by immunoblotting with an anti-nNOS antibody demonstrate predominant localization of native nNOS (WT, wild type) to the sarcoplasmic reticulum and of nNOS.eGFP to the sarcolemmal membrane (n=4 hearts). IgG: negative control.

(B) In WT LV homogenates, a small amount of caveolin-3 is immunoprecipitated with nNOS (n=3).

(C) Steady-state activation curves showed that the voltage at which  $I_{Ca}$  was half-maximally activated was not significantly different between groups ( $-15.6 \pm 0.6$  mV in eGFP vs.  $-18.9 \pm 0.9$  mV in nNOS.eGFP, n=14-18 cells from 4 hearts and  $-15.8 \pm 0.6$  mV in eGFP vs.  $-16.1 \pm 0.6$  mV in nNOS.eGFP in the presence of SMTC, n=6-10 cells from 4 hearts; ANOVA, P=NS).

## Supplementary Figure 2



**Supplementary Figure 2.** (A) Under basal conditions, the voltage of half-maximal inactivation of  $I_{Ca}$  in nNOS.eGFP transduced myocytes was shifted to the left. This difference was abolished after nNOS inhibition with SMTC ( $P=NS$ ,  $n=5$  and  $6$  cells from  $3$  hearts). (B) In the presence of isoproterenol ( $100$  nmol/L), inactivation curves did not differ between nNOS.eGFP ( $n=8$  cells from  $8$  hearts) and eGFP expressing myocytes ( $n=7$  cells from  $7$  hearts) in the presence and absence of SMTC. Under these conditions, the voltage at which  $I_{Ca}$  was half-maximally inactivated was  $-34.5 \pm 2.1$  mV in eGFP vs.  $-33.6 \pm 1.4$  mV in nNOS.eGFP and  $-31.1 \pm 1.2$  in eGFP vs.  $-29.9 \pm 1.2$  mV in nNOS.eGFP in the presence of SMTC; ANOVA with Bonferroni's correction,  $P=NS$ ).